Stay updated with breaking news from Aortic Valve Replacement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The APAC Transcatheter Aortic-Valve Replacement (TAVR) market is projected to grow significantly, with the market size expected to reach approximately USD 3.8 billion by 2033, up from USD 1.2 billion in 2023, reflecting a compound annual growth rate (CAGR) of 12.2% during the forecast period from 2024 to 2033. This...
The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine for late-breaking science on PCI, TAVR, PAD and heart valve studies.
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
A cardiac murmur is an extra whooshing sound during the heartbeat due to the turbulence of blood flow in the heart or blood vessels.